RVMD Stock Overview
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Revolution Medicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.26 |
| 52 Week High | US$38.73 |
| 52 Week Low | US$15.44 |
| Beta | 1.54 |
| 1 Month Change | 19.43% |
| 3 Month Change | 29.64% |
| 1 Year Change | 59.81% |
| 3 Year Change | 7.28% |
| 5 Year Change | n/a |
| Change since IPO | 25.47% |
Recent News & Updates
Recent updates
Revolution Medicines: An Expensive Shot At A Massive Market Opportunity
Apr 12Revolution Medicines Is Hard To Understand
Feb 01Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation
Aug 09
Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates
May 13We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth
Apr 02We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely
Dec 20We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate
Sep 15Revolution Medicines promotes Jack Anders to CFO
Sep 02New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD)
Aug 10Revolution Medicines to raise up to $200M in stock offering
Jul 19Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Slashed This Year's Revenue Estimates By 11%
May 11We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely
Mar 31Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans
Dec 16What Does The Future Hold For Revolution Medicines, Inc. (NASDAQ:RVMD)? These Analysts Have Been Cutting Their Estimates
Aug 17Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans
Aug 03Revolution Medicines EPS misses by $0.01, beats on revenue
May 10Revolution Medicines expects no data from Amgen-sponsored clinical trial for RMC-4630
Apr 30Shareholder Returns
| RVMD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.5% | 1.5% | 1.2% |
| 1Y | 59.8% | 1.1% | 24.7% |
Return vs Industry: RVMD exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: RVMD exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| RVMD volatility | |
|---|---|
| RVMD Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RVMD's share price has been volatile over the past 3 months.
Volatility Over Time: RVMD's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 378 | Mark Goldsmith | www.revmed.com |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets.
Revolution Medicines, Inc. Fundamentals Summary
| RVMD fundamental statistics | |
|---|---|
| Market cap | US$5.97b |
| Earnings (TTM) | -US$436.37m |
| Revenue (TTM) | US$11.58m |
515.7x
P/S Ratio-13.7x
P/E RatioIs RVMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVMD income statement (TTM) | |
|---|---|
| Revenue | US$11.58m |
| Cost of Revenue | US$411.24m |
| Gross Profit | -US$399.66m |
| Other Expenses | US$36.70m |
| Earnings | -US$436.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.65 |
| Gross Margin | -3,451.33% |
| Net Profit Margin | -3,768.28% |
| Debt/Equity Ratio | 0% |
How did RVMD perform over the long term?
See historical performance and comparison